Jianying Hu, PhD, director of healthcare and life sciences research and global science leader of AI for health at IBM, delivered a keynote address at the 3rd a2 National Symposium at the Harvard Club of Boston. She was introduced by Peter Abadir, MD, associate professor of geriatric medicine and gerontology at Johns Hopkins University School of Medicine and co-principal investigator of JH AITC.
Dr. Hu’s talk focused on the transformative role of artificial intelligence in advancing therapeutic strategies for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s. She highlighted how AI can accelerate drug discovery, improve disease progression modeling, and support drug repurposing through causal inference methodologies. Her presentation underscored the value of AI in tackling the complexity and cost of developing effective treatments.
This keynote exemplifies the a2 Collective’s mission to translate AI innovation into meaningful improvements in aging and dementia care. Watch the full video above to explore how AI is shaping the future of neurodegenerative therapeutics.
